Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway
| Autor: | Yujun Guo, Qin Qin, Bei Ren, Cheng Chen, Ning Yang, Jin-ping Feng |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Ginsenosides Inflammasomes Immunology Anti-Inflammatory Agents Inflammation Pharmacology medicine.disease_cause Muscle hypertrophy Immunomodulation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Sirtuin 1 Western blot Fibrosis NLR Family Pyrin Domain-Containing 3 Protein medicine Animals Humans Immunology and Allergy Myocytes Cardiac Aorta Cells Cultured medicine.diagnostic_test Chemistry Angiotensin II Myocardium NF-kappa B Inflammasome NF-κB Hypertrophy medicine.disease Rats Disease Models Animal Oxidative Stress 030104 developmental biology 030220 oncology & carcinogenesis medicine.symptom Oxidative stress Signal Transduction medicine.drug |
| Zdroj: | International Immunopharmacology. 98:107841 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2021.107841 |
| Popis: | Background Ginsenoside Rg3 (Rg3), one of the most potent components extracted from the roots of the traditional Chinese herb Panax ginseng, has prominent roles in anti-tumor and anti-inflammation. However, the applications of Rg3 against myocardial hypertrophy are not fully revealed. Methods Transverse aortic constriction (TAC) was adopted to build the myocardial hypertrophy model in rats. The in vitro model of myocardial hypertrophy was induced by angiotensin II (Ang II) in the human cardiomyocyte cell line AC16 and HCM, which were then treated with different doses of Rg3. The levels of myocardial hypertrophy markers (ANP, BNP, and β-MHC) were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Western blot (WB) was conducted to verify the expressions of myocardial fibrosis-associated proteins (MyHc, Collagen Ⅰ, and TGF-β1) and oxidative stress (OS) proteins (HO-1 and Nrf2). The markers of fibrosis, hypertrophy, NLRP3 inflammasome and OS in cardiomyocytes were evaluated by qRT-PCR, western blot (WB), enzyme-linked immunosorbent assay (ELISA), and cellular immunofluorescence, respectively. Furthermore, pharmacological intervention on sirtuin-1 (SIRT1) was performed to clarify the function of SIRT1 in Rg3-mediated effects. Results Rg3 dose-dependently attenuated the Ang II-induced myocardial hypertrophy and fibrosis. What’s more, Rg3 markedly inhibited NLRP3-ASC-Caspase1 inflammasome and OS (reflected by SOD, MDA, HO-1, and Nrf2) in cardiomyocytes treated with Ang II. Mechanistically, Rg3 attenuated NF-κB activation and promoted SIRT1 expression. Inhibiting SIRT1 (by AGK2) mostly reversed Rg3-mediated effects against Ang II-induced myocardial hypertrophy and fibrosis. In the TAC rat model, administration of Rg3 mitigated myocardial hypertrophy and fibrosis through pressing overproduced inflammation and OS. Conclusion Rg3 prevents Ang II-induced myocardial hypertrophy via inactivating NLRP3 inflammasome and oxidative stress by modulating the SIRT1/NF-κB pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect